2,882 results match your criteria Future Oncology[Journal]


Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

Future Oncol 2019 Feb 13. Epub 2019 Feb 13.

Boehringer Ingelheim Pharma GmbH & Co, KG, Germany & Institute of Pharmacology, Johannes Gutenberg-University Mainz, Germany.

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has 'aggressive disease', as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low programmed death-ligand 1 expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0948DOI Listing
February 2019

FMO1 gene expression independently predicts favorable recurrence-free survival of classical papillary thyroid cancer.

Future Oncol 2019 Feb 13. Epub 2019 Feb 13.

Department of Vascular & Thyroid Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science & Technology of China, Chengdu 610072, Sichuan, China.

Aim:  To examine the expression profile of FMO1 in papillary thyroid cancer (PTC) and its prognostic value in recurrence-free survival (RFS).

Methods:  A retrospective analysis was performed using data from the Cancer Genome Atlas and Human Protein Atlas.

Results: The most frequent variants of PTC had decreased FMO1 expression compared with their respective adjacent normal tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0885DOI Listing
February 2019

Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA.

Future Oncol 2019 Feb 13. Epub 2019 Feb 13.

Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA 02139, USA.

Aim: To evaluate treatment patterns of diffuse large B-cell lymphoma (DLBCL).

Patients & Methods: First-line and relapsed/refractory treatment patterns and survival outcomes following first-line therapy in adult patients newly diagnosed with DLBCL were evaluated.

Results: A total of 1436 DLBCL patients initiated treatment and mainly received a combination regimen versus monotherapy (92. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0788DOI Listing
February 2019

Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis.

Future Oncol 2019 Feb 11. Epub 2019 Feb 11.

Department of Kidney Disease & Blood Purification Treatment, Tianjin Institute of Urology, the Second Hospital of Tianjin Medical University, Tianjin 300211, China.

Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed in recent randomized controlled trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0619DOI Listing
February 2019

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

Future Oncol 2019 Feb 8. Epub 2019 Feb 8.

National Cancer Center Hospital East, 6-5-1 Kashiwanoha, Kashiwa, 277-8577, Japan.

Background: Treatment options for patients with advanced esophageal or esophagogastric junction (EGJ) cancer are limited. Current guidelines for first-line treatment of advanced esophageal or EGJ cancer recommend chemotherapy containing a platinum and a fluoropyrimidine agent. Pembrolizumab demonstrated antitumor activity in previously treated patients with advanced esophageal cancer and in patients with gastroesophageal junction cancer. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0609
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0609DOI Listing
February 2019
4 Reads

Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.

Future Oncol 2019 Feb 8. Epub 2019 Feb 8.

Icahn School of Medicine, Center for Carcinoid and Neuroendocrine Tumors, Mount Sinai Health System, New York, NY 10029, USA.

Aim: Elevated serotonin in patients with neuroendocrine tumors (NETs) may impact heart failure incidence but a quantitative relationship has not been established.

Materials & Methods: Systematic review and meta-analysis of studies assessing 24-h urinary 5-hydroxyindoleacetic acid (u5-HIAA) and mortality in patients with NETs (2007-2017) with a primary outcome of 1-year mortality risk and 24-h u5-HIAA.

Results: We identified 1715 records of which 12 studies including 755 patients (3442 person-years with 376 deaths) were eligible for meta-analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0960DOI Listing
February 2019

S6K2 promises an important therapeutic potential for cancer.

Future Oncol 2019 Jan 1;15(1):95-102. Epub 2018 Nov 1.

Department of Molecular Biology & Genetics, Faculty of Science & Letters, Pamukkale University, Denizli, Turkey.

S6K2, the newer member of S6 Kinase family, is a crucial modulator of Akt/mTOR signaling pathway and is a member of AGC kinase family that regulates cellular growth and survival. S6K1 and S6K2 share high sequence similarity; therefore, S6K2 had been underestimated. However, recent studies displayed distinct functions of S6K2. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0332DOI Listing
January 2019
2 Reads

Welcome to the 15th volume of Future Oncology.

Authors:
Rachel Jenkins

Future Oncol 2019 Jan;15(1):1-3

Future Science Group, Unitec House, 2 Albert Place, London N3 1QB, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0782DOI Listing
January 2019

Treatment of aggressive non-Hodgkin's lymphoma in frail patients: cardiac comorbidities and advanced age.

Future Oncol 2019 Feb 7. Epub 2019 Feb 7.

Hematology, Azienda USL IRCCS Reggio Emilia, Italy.

The decisive factor in selecting a treatment regimen for a frail patient with aggressive non-Hodgkin's lymphoma is identifying whether a patient is fit enough to tolerate curative-intent anthracycline-containing regimens or too frail and therefore at risk of being undertreated. As cardiac comorbidities are an important contributor to both the health status and the selection of treatment, cardiovascular profiling and baseline risk stratification prior to treatment should be considered. Comprehensive geriatric assessment is an efficient means of identifying elderly patients with non-Hodgkin's lymphoma who may benefit from a curative treatment approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0019DOI Listing
February 2019
2 Reads

Cannabinoids: the lows and the highs of chemotherapy-induced nausea and vomiting.

Future Oncol 2019 Feb 5. Epub 2019 Feb 5.

Department of Physiological Sciences, Stellenbosch University, Stellenbosch, 7600, South Africa.

Despite remaining one of the most widely abused drugs worldwide, Cannabis sativa exhibits remarkable medicinal properties. The phytocannabinoids, cannabidiol and Δ-9-tetrahydrocannabinol, reduce nausea and vomiting, particularly during chemotherapy. This is attributed to their ability to reduce the release of serotonin from enterochromaffin cells in the small intestine, which would otherwise orchestrate the vomiting reflex. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0530DOI Listing
February 2019

Overall survival, costs and healthcare resource use by number of regimens received in elderly patients with newly diagnosed metastatic triple negative breast cancer.

Future Oncol 2019 Feb 5. Epub 2019 Feb 5.

Pharmerit International, 4350 East-West Hwy, Suite 1110, Bethesda, MD 20814, USA.

Aim: This analysis estimated the overall survival, treatment patterns and economic burden of elderly metastatic triple-negative breast cancer patients.

Materials & Methods: Patients (≥66 years) with metastatic triple-negative breast cancer were identified from the SEER-Medicare database. Treatment patterns were defined in terms of first, second and third or more regimens. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0407DOI Listing
February 2019

The pretreatment platelet count is an independent predictor of tumor progression in patients undergoing transcatheter arterial chemoembolization with hepatitis B virus-related hepatocellular carcinoma.

Future Oncol 2019 Feb 4. Epub 2019 Feb 4.

Department of Hematology, Zhongshan Hospital Fudan University, Shanghai 200032, PR China.

Aim: To explore the prognostic value of the pretreatment platelet (PLT) count in patients undergoing transcatheter arterial chemoembolization (TACE) with hepatocellular carcinoma (HCC).

Materials & Methods: We prospectively analyzed 317 hepatitis B virus-related HCC patients undergoing TACE. Time to progression (TTP) was selected to evaluate the clinical significance of PLT level in HCC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0591DOI Listing
February 2019
2 Reads
2.477 Impact Factor

Sunitinib in patients with pancreatic neuroendocrine tumors: update of safety data.

Future Oncol 2019 Jan 31. Epub 2019 Jan 31.

Paris Saint-Joseph Hospital Group, 185 Rue Raymond Losserand, Paris 75014, France.

Aim: To describe the long-term safety of sunitinib in patients with progressive, well-differentiated, advanced/metastatic pancreatic neuroendocrine tumors.

Patients & Methods: Sunitinib- and placebo-treated patients from the Phase III study continued to receive sunitinib (37.5 mg on a continuous daily-dosing regimen) in two open-label extension studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0882DOI Listing
January 2019
2 Reads

Patient preferences for treatment of metastatic melanoma.

Future Oncol 2019 Jan 29. Epub 2019 Jan 29.

Novartis Pharmaceuticals Corporation, East Hanover, NJ 07936, USA.

Aim: To investigate patient preferences for clinical attributes of first-line metastatic melanoma treatments.

Materials & Methods: A discrete-choice experiment and best-worst scaling exercise were used to assess relative preferences for treatment attributes.

Results: The 200 survey respondents had distinct preferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0871DOI Listing
January 2019

Hot topics in epigenetic regulation of cancer self-renewal for pancreatic tumors: future trends.

Future Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Biomedical Sciences & Medicine, Algarve Biomedical Center, Division of Oncology, University of Algarve, 8005-139 Faro, Portugal.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0153DOI Listing
January 2019

Radiosensitivity nomogram based on circulating neutrophils in thoracic cancer.

Future Oncol 2019 Jan 29. Epub 2019 Jan 29.

Department of Radiation Oncology, Qianfoshan Hospital affiliated to Shandong University, Shandong University, 16766 Jingshi Road, Jinan, 250014, PR China.

Aim: To evaluate the prediction ability of neutrophils and develop a nomogram on radiosensitivity in thoracic cancer patients.

Methods: We retrospectively reviewed 398 lung and esophageal cancers patients who received external-beam radiotherapy or concurrent chemoradiotherapy as first-line therapy.

Results: Logistic regression model showed that patients with low levels of neutrophil counts and/or TGF-β1 exhibited better radiation sensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0398DOI Listing
January 2019

Guidance of sentinel lymph node biopsy decisions in patients with T1-T2 melanoma using gene expression profiling.

Future Oncol 2019 Jan 29. Epub 2019 Jan 29.

Division of Surgical Oncology, Department of Surgery, The University of Tennessee Health Science Center, Memphis, TN 38163, USA.

Aim: Can gene expression profiling be used to identify patients with T1-T2 melanoma at low risk for sentinel lymph node (SLN) positivity?

Patients & Methods: Bioinformatics modeling determined a population in which a 31-gene expression profile test predicted <5% SLN positivity. Multicenter, prospectively-tested (n = 1421) and retrospective (n = 690) cohorts were used for validation and outcomes, respectively.

Results: Patients 55-64 years and ≥65 years with a class 1A (low-risk) profile had SLN positivity rates of 4. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0912
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0912DOI Listing
January 2019
3 Reads

Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale.

Future Oncol 2019 Jan 28. Epub 2019 Jan 28.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Aim: Lenvatinib plus everolimus is approved for the treatment of advanced renal cell carcinoma (RCC) after one prior vascular endothelial growth factor-targeted therapy. Lenvatinib plus pembrolizumab demonstrated promising antitumor activity in a Phase I/II trial of RCC.

Methods: We describe the rationale and design of the CLEAR study, a three-arm Phase III trial comparing lenvatinib plus everolimus and lenvatinib plus pembrolizumab versus sunitinib monotherapy for first-line treatment of RCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0745DOI Listing
January 2019

Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review.

Future Oncol 2019 Jan 25. Epub 2019 Jan 25.

Ospedale San Gerardo, Via GB Pergolesi 33, 20052 Monza, Italy.

Aim: We investigated outcomes in patients with advanced non-small-cell lung cancer (NSCLC) and peritoneal involvement.

Patients & Methods: NSCLC patients with peritoneal carcinomatosis (PC) were included. We evaluated mOS1 (overall survival [OS] from NSCLC diagnosis) and mOS2 (OS from diagnosis of PC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0469DOI Listing
January 2019
2 Reads

Corrigendum.

Authors:

Future Oncol 2019 Feb 10;15(4):451. Epub 2018 Oct 10.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2017-0669c1DOI Listing
February 2019

Impact of socioeconomic inequalities on quality of life in oral submucous fibrosis patients.

Future Oncol 2019 Jan 23. Epub 2019 Jan 23.

Department of Oral Pathology & Microbiology, Dr DY Patil Dental College & Hospital, Dr DY Patil Vidyapeeth, Pune, Maharashtra, India.

Aim: The purpose of this study was to analyze the impact of socioeconomic characteristics on oral health-related quality of life (OHRQoL) in patients with oral submucous fibrosis (OSF).

Methods:  A total of 300 OSF patients' quality of life (QoL) data were obtained using OHRQoL-OSF and global self ratings of oral health and overall wellbeing. The socioeconomic status (SES) of participants was analyzed by using modified Kuppuswamy scale. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0645DOI Listing
January 2019
2.477 Impact Factor

Comparison of second-line treatments of recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Future Oncol 2019 01 23. Epub 2019 Jan 23.

Department of Hematology-Oncology, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Aim: The literature lacks direct evidence comparing the different regimens evaluated in the second-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Methods: We conducted a network meta-analysis (NMA) of the randomized controlled Phase III trials reporting on the second-line drug treatment options in R/M SCCHN.

Results: The eligible trials included 11 regimens among which six targeted therapies, two immune checkpoint inhibitors and three chemotherapy regimens. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0663
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0663DOI Listing
January 2019
11 Reads
2.477 Impact Factor

Subgroups of parotid gland infiltrating ductal carcinoma benefit from postoperative radiotherapy: a population-based study.

Future Oncol 2019 Jan 22. Epub 2019 Jan 22.

Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.

Aim: To analyze the prognostic factors and the impact of postoperative radiotherapy (PORT) in parotid gland infiltrating ductal carcinoma (IDC).

Materials & Methods: 252 patients diagnosed with parotid gland IDC were identified from the SEER database. Kaplan-Meier and Cox regression analysis was performed to evaluate the prognostic factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0495DOI Listing
January 2019

Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer.

Future Oncol 2019 Jan 18. Epub 2019 Jan 18.

Department of Hematology & Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA.

Mutations in the EGFR occur in approximately 10-35% of non-small-cell lung cancer (NSCLC) patients. Osimertinib is a third-generation oral small molecule inhibitor of EGFR, active against the common targetable activating EGFR mutations in L858R and exon 19 deletion; it also inhibits the T790M mutation. It was initially developed and approved for the treatment of acquired resistance to EGFR inhibition mediated by the T790M pathway activation. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0626
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0626DOI Listing
January 2019
14 Reads

Comparison of different prognostic models for predicting cancer-specific survival in bladder transitional cell carcinoma.

Future Oncol 2019 Jan 18. Epub 2019 Jan 18.

The School of Traditional Chinese Medicine of Jinan University, Guangzhou 510632, Guangdong Province, PR China.

Objective: To construct the newly valuable nomogram which can compare the predictive performance with American Joint Committee on Cancer (AJCC) staging system in bladder transitional cell carcinoma (BTCC).

Methods: BTCC patients were screened (2004-2015) from the SEER database. The nomogram incorporating lymph node ratio was constructed to evaluate individualized cancer-specific survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0695DOI Listing
January 2019

Comorbidities in elderly patients with glioblastoma: a field-practice study.

Future Oncol 2019 Jan 18. Epub 2019 Jan 18.

Neuro-Oncology Unit, 'Regina Elena' National Cancer Institute, Via Elio Chianesi 53, 00144 Rome, Italy.

Aim: This single-center study evaluated the effect of comorbidities on progression-free and overall survival in elderly patients with glioblastoma multiforme (GBM).

Patients & Methods: Comorbid conditions were identified in each patient with the modified version of the cumulative illness rating scale (CIRS).

Results:  Total of 118 patients with GBM were enrolled. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0524
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0524DOI Listing
January 2019
5 Reads

Comparison of cardiovascular effects of crizotinib and chemotherapy in ALK-positive advanced non-small-cell lung cancer.

Future Oncol 2019 Jan 17. Epub 2019 Jan 17.

Pfizer Inc., New York, NY 10017, USA.

Aim: We analyzed cardiac function in two Phase III studies of previously treated (PROFILE 1007) or untreated (PROFILE 1014) ALK-positive advanced non-small-cell lung cancer.

Patients & Methods: Adverse events associated with cardiac failure were compared between treatment arms in each study separately. Cardiac function was assessed prospectively by multigated acquisition scans or echocardiograms. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0869
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0869DOI Listing
January 2019
3 Reads

Why have microRNA biomarkers not been translated from bench to clinic?

Future Oncol 2019 Jan 17. Epub 2019 Jan 17.

Hematology, Oncology & Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0812DOI Listing
January 2019

Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue.

Future Oncol 2019 Feb 16;15(6):563-565. Epub 2019 Jan 16.

Division of Oncology, Sant'Orsola-Malpighi Hospital, Bologna, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0758DOI Listing
February 2019
3 Reads

Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance.

Future Oncol 2019 Feb 16;15(6):653-662. Epub 2019 Jan 16.

Department of Pathology, School of Basic Medicine, Medical Department of Qingdao University, Qingdao 266071, Shandong Province, PR China.

The receptor tyrosine kinase Axl and its ligand Gas6 regulate fundamental biological processes, including cell proliferation, survival and motility, through multiple downstream signaling pathways. Evidence to date suggests that aberrant Axl expression frequently occurs in many malignancies, including hepatocellular carcinoma, and that this is critical for promoting cell proliferation, migration, angiogenesis and metastasis. Moreover, deregulated Axl expression or activation is reportedly associated with resistance to cancer drugs and targeted cancer therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0528DOI Listing
February 2019

The inhibition effect of cold atmospheric plasma-activated media in cutaneous squamous carcinoma cells.

Future Oncol 2019 Feb 16;15(5):495-505. Epub 2019 Jan 16.

Department of Dermatology, The First Affiliated Hospital, Anhui Medical University, Hefei, Anhui, PR China.

Aim: This study investigated the effect and mechanism of cold atmospheric plasma (CAP)-activated media on A431 and HaCaT cells.

Materials & Methods: Phosphate-buffered saline (PBS) and Dulbecco's Modified Eagle's Medium (DMEM) were treated by CAP to get CAP-activated media. A431 and HaCaT were incubated by CAP-activated media for 2 h. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0419DOI Listing
February 2019

Prognostic  value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer.

Future Oncol 2019 Jan 15. Epub 2019 Jan 15.

Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Science, Jinan, PR China.

Aim: To dynamically investigate the prognostic value of albumin-to-alkaline phosphatase ratio (AAPR) in limited stage small-cell lung cancer.

Materials & Methods:  The AAPR within 1 week before and after chemoradiation therapy (pre- and post-AAPR) was collected and analyzed.

Results: Patients with low pre- or post-AAPR had shorter overall survival and progression-free survival than the high groups (p all < 0. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0818
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0818DOI Listing
January 2019
5 Reads

Ramucirumab and its use in the treatment of hepatocellular carcinoma.

Future Oncol 2019 Jan 15. Epub 2019 Jan 15.

Department of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK.

Ramucirumab is a fully humanized monoclonal antibody directed selectively at VEGFR-2 - a key player in the VEGF orchestra and angiogenic process. It has demonstrated clinical efficacy and a favorable safety profile in the treatment of a number of malignancies including gastric, lung, urothelial, colorectal and, most recently, advanced liver cancer. This article describes the recent Phase III trial results of ramucirumab in patients with hepatocellular carcinoma, including safety data and patient-reported outcomes, with particular emphasis on efficacy data in the patient population with baseline α-fetoprotein levels ≥400 ng/ml, traditionally considered a poor prognostic group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0822DOI Listing
January 2019

A Phase II study of the safety and efficacy of lenvatinib in patients with advanced thyroid cancer.

Future Oncol 2019 Jan 14. Epub 2019 Jan 14.

Department of Head & Neck Medical Oncology, National Cancer Center Hospital East, Kashiwa, Japan.

Aim: To investigate the safety and efficacy of lenvatinib in advanced thyroid cancer.

Patients/methods: In this Phase II study, 51 Japanese patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC), medullary thyroid cancer (MTC) or anaplastic thyroid cancer (ATC) received once-daily lenvatinib 24 mg. The primary end point was safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0557DOI Listing
January 2019
1 Read

Cobimetinib in malignant melanoma: how to MEK an impact on long-term survival.

Future Oncol 2019 Jan 14. Epub 2019 Jan 14.

Unit of Medical Oncology, Department of Oncology & Hematology, Papa Giovanni XXIII Hospital, Bergamo, Italy.

Approximately 50% of cutaneous melanomas harbor activating mutations of the BRAF-oncogene, making BRAF inhibitors (BRAFi) the standard treatment for this disease. However, disease responses are limited in duration mainly due to acquired resistance. Dual MAPK pathway inhibition with addition of a MEK inhibitor (MEKi) to a BRAFi improved the efficacy and tolerability compared with BRAFi alone. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0659
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0659DOI Listing
January 2019
3 Reads

Low expression of CD80 predicts for poor prognosis in patients with gastric adenocarcinoma.

Future Oncol 2019 Feb 10;15(5):473-483. Epub 2019 Jan 10.

Biotherapy Center, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Guangzhou 510060, PR China.

Aim: To study the expression and prognostic significance of CD80 in patients with gastric adenocarcinoma. Materials & methods: Real-time quantitative PCR, western blot and immunohistochemistry were performed to detect the expression of CD80 in gastric cancer tissues and matched adjacent normal tissues. Double immunohistochemical staining was performed to preliminary examine the relationship between CD80 cells and CD8 cytotoxic T lymphocytes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0420DOI Listing
February 2019

Immunotherapy: last bullet in platinum refractory germ cell testicular cancer.

Future Oncol 2019 Feb 9;15(5):533-541. Epub 2019 Jan 9.

Urology Department, Faculty of Medicine, Saint-Joseph University, Beirut, Lebanon.

Testicular germ cell tumors are chemosensitive with very high cure-rates even in the metastatic setting. However, patients with platinum-refractory and relapsing tumors after autologous stem cell transplant have very poor outcomes despite salvage treatments, and with no effective alternative therapies. Immunotherapy, notably with PD-1 inhibitors, has proven to be very effective in treating various solid tumors. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0571
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0571DOI Listing
February 2019
18 Reads

Bone metastases and skeletal-related events: incidence and prognosis according to histological subtype of lung cancer.

Future Oncol 2019 Feb 9;15(5):485-494. Epub 2019 Jan 9.

Research Center, National Cancer Institute, Rio de Janeiro, Brazil.

Aim: Estimate the incidence of bone metastases (BM) and skeletal-related events according to the histological subtype of lung cancer and its impact on patient survival.

Patients & Methods: Retrospective cohort study was carried out with patients diagnosed with lung cancer. Cumulative incidence, Kaplan-Meier survival analysis and the risk of death were estimated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0613DOI Listing
February 2019

Clinical outcome and prognostic analysis of young adults nasopharyngeal carcinoma patients of a nonendemic area in intensity-modulated radiotherapy era.

Future Oncol 2019 Feb 8;15(4):381-389. Epub 2019 Jan 8.

Department of Radiation Oncology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science & Technology of China, Chengdu, PR China.

Aim: To investigate the clinical outcome and prognostic factors of young adults nasopharyngeal carcinoma (NPC) patients in the era of intensity-modulated radiotherapy.

Methods: We retrospectively analyzed the clinical outcome and the prognostic factors of young adults NPC patients who were admitted to our hospital from January 2010 to December 2013. COX regression model was used to identify factors associated with survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0547DOI Listing
February 2019

Critical systematic review on hepatic resection and transarterial chemoembolization for hepatocellular carcinoma.

Future Oncol 2019 Feb 8;15(4):439-449. Epub 2019 Jan 8.

General and Oncology Surgery, Morgagni-Pierantoni Hospital, Forli, 47121, Italy.

Whether to submit to transarterial chemoembolization (TACE) or hepatic resection (HR) patients with hepatocellular carcinoma (HCC) is still a debated issue. We conducted a systematic review to critically analyze what evidence supports the use of TACE, in a specific clinical condition that can define HCC as 'intermediate'. In addition, we analyzed literature regarding the comparison between TACE and HR. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0269
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0269DOI Listing
February 2019
1 Read

Could JAG1 protein inhibition prevent colorectal cancer?

Future Oncol 2019 Feb 8;15(4):345-347. Epub 2019 Jan 8.

Cancer Research Program, Institut Mar d'Investigacions Mèdiques, CIBERONC, Hospital del Mar, Doctor Aiguader 88, Barcelona 08003, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0760DOI Listing
February 2019

The predictive value of the prognostic staging system in the 8th edition of the American Joint Committee on Cancer for triple-negative breast cancer: a SEER population-based analysis.

Future Oncol 2019 Feb 8;15(4):391-400. Epub 2019 Jan 8.

Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.

Aim: To examine the stage changes and survival differences among triple-negative breast cancer (TNBC) patients based on the prognostic staging system.

Methods: We used the SEER database to identify eligible patients with TNBC diagnosed between 2010 and 2014. Kaplan-Meier curves were drawn for comparison. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0145DOI Listing
February 2019

Signet ring cell component, not the Lauren subtype, predicts poor survival: an analysis of 198 cases of gastric cancer.

Future Oncol 2019 Feb 8;15(4):401-408. Epub 2019 Jan 8.

Department of Oncology, Hospital Israelita Albert Einstein, São Paulo, Brazil.

Aim: Prognostic differences between major histologic gastric cancer groups, intestinal and diffuse are uncertain, since cellular components in each of them possibly have different behaviors.

Materials & Methods: We reviewed 198 gastric cancer patients charts diagnosed from January 2003 to December 2015 in a tertiary hospital. Multivariate Cox proportional survival models were used to evaluate the impact of histologic groups on overall survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0354DOI Listing
February 2019

Female oncofertility attitude and knowledge: a survey of reproductive health professionals in Shanghai, China.

Future Oncol 2019 Feb 8;15(4):371-379. Epub 2019 Jan 8.

Department of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, SC 29208, USA.

Aim: To evaluate the female oncofertility attitude and knowledge of reproductive health professionals in China.

Methods: An online survey was distributed to reproductive health professionals in Shanghai, China.

Results: Female professionals were more likely to consider that cancer patients would want to preserve their fertility. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0428
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0428DOI Listing
February 2019
5 Reads

99mTc sestamibi SPECT: a possible tool for early detection of breast cancer lesions with high bone metastatic potential.

Future Oncol 2019 Feb 8;15(5):455-457. Epub 2019 Jan 8.

Department of Biomedicine & Prevention, University of Rome "Tor Vergata", Via Montpellier 1, 00133 Rome, Italy.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0735
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0735DOI Listing
February 2019
3 Reads

HTX-019 via 2-min injection or 30-min infusion in healthy subjects.

Future Oncol 2018 Dec 21. Epub 2018 Dec 21.

Heron Therapeutics, Inc., 4242 Campus Point Court, Suite 200, San Diego, CA 92121, USA.

Aim: HTX-019 (CINVANTI [aprepitant injectable emulsion]) is a neurokinin 1 receptor antagonist approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 is free of polysorbate 80 and other synthetic surfactants and showed bioequivalence to and a more favorable safety profile than fosaprepitant when administered as a 30-min infusion in healthy subjects. The shortage of small-volume parenteral solutions led to a recommendation to administer HTX-019 by intravenous push. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0809
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0809DOI Listing
December 2018
11 Reads

Nilotinib in the treatment of chronic myeloid leukemia.

Future Oncol 2018 Dec 14. Epub 2018 Dec 14.

Division of Hematology & Internal Medicine, Department of Clinical & Biological Sciences of the University of Turin, 'San Luigi Gonzaga' University Hospital, 10043 Orbassano-Turin, Italy.

Nilotinib, a second-generation tyrosine kinase inhibitor, was designed to overcome resistance of a wide range of BCR-ABL mutants to imatinib. When used in the first-line treatment in newly diagnosed  chronic myeloid leukemia (CML), it induces faster and deeper molecular responses in higher than imatinib percentage of patients. Treatment-free remission after achievement of sustained deep molecular response represents an emerging treatment goal for a proportion of patients with CML in chronic phase. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0468
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0468DOI Listing
December 2018
6 Reads

Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes.

Future Oncol 2019 Jan 13;15(3):281-295. Epub 2018 Dec 13.

Department of General Surgery, Changhai Hospital, Second Military Medical University, 168 Changhai Road, Shanghai 200433, PR China.

Aim: USP22, a member of ubiquitin-specific proteases (USPs), is a well-defined protein that promotes poor prognosis, invasion and metastasis, and also participates in the maintenance of cancer stem cells. USP22 siRNA-loaded nanoliposomes conjugated with CD44 antibodies (USP22-NLs-CD44) were constructed to enhance the therapeutic effect of USP22 siRNA against gastric cancer stem cells.

Materials & Methods: The targeting and therapeutic efficacies of USP22-NLs-CD44 against gastric cancer stem cells were evaluated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0295DOI Listing
January 2019

Molecular characterization of testicular germ cell tumors: chasing the underlying pathways.

Future Oncol 2019 Jan 7;15(3):227-229. Epub 2018 Dec 7.

Departments of Pathology & Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2018-0617DOI Listing
January 2019
9 Reads

Skin adverse events in recently approved targeted therapies in solid malignancies.

Future Oncol 2019 Jan 7;15(3):331-343. Epub 2018 Dec 7.

Unité de Génétique Médicale, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Targeted anticancer therapies are an important weapon in the fight against cancer. Targeted therapies interfere with specific molecules necessary for tumor growth and cancer progression. They are divided mainly to either monoclonal antibodies or small molecules inhibitors. Read More

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/fon-2018-0402
Publisher Site
http://dx.doi.org/10.2217/fon-2018-0402DOI Listing
January 2019
8 Reads